CIRSE launches Europe-wide registry to study irinotecan-loaded LifePearl microspheres

340

A new European‰Ûwide observational study to prospectively gather data on patients treated with irinotecan‰Ûloaded microspheres has been launched by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The CIRSE Registry for LifePearl microspheres (CIREL) will begin early in 2016.

The CIRSE Registry for Lifepearl Microspheres (CIREL) will prospectively observe the administration of irinotecan‰Ûeluting microspheres, a newly CE‰Ûapproved transcatheter chemoembolization (TACE) system. CIREL marks the second major observational study led solely by CIRSE. The primary endpoint is to map the exact indications for which the embolic agent is being used and to identify the stage in treatment at which it is being applied.

Supported by a grant provided by Terumo Europe, the study will be overseen by a multidisciplinary Steering Committee made up of renowned experts including chairmen Philippe Pereira (director Clinic of Radiology, Minimally Invasive Therapies and Nuclear Medicine Heilbronn, Heilbronn, Germany) and Julien Taieb (Gastroenterology, Hopital Européen George Pompidou, Paris, France).

Enthused by the endeavour, Pereira remarked: “This observational study will not only provide us with robust, multicentre data on the precise use and efficacy and safety profiles of this particular device, but also give some insight into how TACE can fit into the established lines of standard clinical practice in Europe.”